

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia, and acute myeloid leukaemia
<http://guidance.nice.org.uk/TA/Wave18/19>

Dear Consultees and commentators,

The Appraisal Committee met on 3 September to discuss the comments received on the ACD for this appraisal.

The manufacturer of azacitidine submitted substantial additional analyses as part of their response to the ACD. The Appraisal Committee has concluded that further review of these additional analyses is required, including clarification of aspects of the additional modelling from the manufacturer, before it can make its decision.

We will inform you of the updated timelines for this appraisal as soon as possible. If you have any questions, please contact me.

Best wishes,

Jeremy

Jeremy Powell

Technology Appraisal Project Manager

National Institute for Health and Clinical Excellence

MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom

Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830